PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.23%
Negative revenue growth while MCHP stands at 6.47%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.26%
Negative gross profit growth while MCHP is at 7.33%. Joel Greenblatt would examine cost competitiveness or demand decline.
-9.56%
Negative EBIT growth while MCHP is at 29.90%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.12%
Negative operating income growth while MCHP is at 27.63%. Joel Greenblatt would press for urgent turnaround measures.
-12.95%
Negative net income growth while MCHP stands at 15.83%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12.96%
Negative EPS growth while MCHP is at 16.46%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.15%
Negative diluted EPS growth while MCHP is at 16.88%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Slight or no buybacks while MCHP is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Dividend growth under 50% of MCHP's 9.02%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-43.19%
Negative OCF growth while MCHP is at 12.40%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-83.44%
Negative FCF growth while MCHP is at 13.49%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
85.25%
10Y revenue/share CAGR under 50% of MCHP's 289.58%. Michael Burry would suspect a lasting competitive disadvantage.
25.26%
5Y revenue/share CAGR under 50% of MCHP's 67.36%. Michael Burry would suspect a significant competitive gap or product weakness.
35.02%
3Y revenue/share CAGR 1.25-1.5x MCHP's 27.50%. Bruce Berkowitz might see better product or regional expansions than the competitor.
293.27%
10Y OCF/share CAGR at 75-90% of MCHP's 355.24%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
13.06%
Below 50% of MCHP's 101.84%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
39.92%
3Y OCF/share CAGR under 50% of MCHP's 89.63%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
475.86%
Net income/share CAGR 1.25-1.5x MCHP's 350.19%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
35.51%
Below 50% of MCHP's 146.35%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
49.34%
Below 50% of MCHP's 759.13%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
69.87%
10Y equity/share CAGR at 50-75% of MCHP's 106.96%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
55.24%
5Y equity/share CAGR 1.25-1.5x MCHP's 45.14%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
102.31%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
491.84%
10Y dividend/share CAGR above 1.5x MCHP's 57.78%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
99.55%
5Y dividend/share CAGR above 1.5x MCHP's 52.92%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
37.31%
3Y dividend/share CAGR at 50-75% of MCHP's 50.86%. Martin Whitman might see a weaker short-term approach to distributing cash.
-0.95%
Firm’s AR is declining while MCHP shows 6.75%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
19.26%
Inventory growth well above MCHP's 6.72%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
7.40%
Asset growth above 1.5x MCHP's 0.05%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.45%
BV/share growth above 1.5x MCHP's 1.74%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
11.53%
We have some new debt while MCHP reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
4.84%
R&D growth drastically higher vs. MCHP's 3.82%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
10.49%
SG&A growth well above MCHP's 0.91%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.